Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40272
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nasreddine, Rakan | - |
dc.contributor.author | Florence, Eric | - |
dc.contributor.author | Yombi, Jean Cyr | - |
dc.contributor.author | Henrard, Sophie | - |
dc.contributor.author | Darcis, Gilles | - |
dc.contributor.author | Van Praet, Jens | - |
dc.contributor.author | Vandekerckhove, Linos D. | - |
dc.contributor.author | Allard, Sabine | - |
dc.contributor.author | Demeester, Remy | - |
dc.contributor.author | MESSIAEN, Peter | - |
dc.contributor.author | Ausselet, Nathalie | - |
dc.contributor.author | Delforge, Marc | - |
dc.contributor.author | De Wit, Stephane | - |
dc.date.accessioned | 2023-06-05T08:43:31Z | - |
dc.date.available | 2023-06-05T08:43:31Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-06-02T14:15:43Z | - |
dc.identifier.citation | HIV MEDICINE, 24 (8) , p. 914-924 | - |
dc.identifier.issn | 1464-2662 | - |
dc.identifier.uri | http://hdl.handle.net/1942/40272 | - |
dc.description.abstract | Objectives: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real-world setting in Belgium.Methods: This was a retrospective, multicentre cohort study involving adult treatment-naive (TN) and treatment-experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV-1 viral load <50 copies/mL; on-treatment analysis) at weeks 24 and 48. The main secondary outcomes included loss of virological suppression (LVS; two consecutive viral loads of >200 copies/mL after being virologically suppressed) by week 48 and analysis of resistance-associated mutations at time of LVS; tolerability of BIC/FTC/TAF over the 48-week study period; and change in weight and proportion of participants reporting a >10% weight gain at week 48.Results: Overall, 2001 participants were included. Through 48 weeks, overall rate of virological suppression was 93.5%, with similar results observed in the following subgroups: age =50 years (92.7%), women (92.8%), Black sub-Saharan African (91%), TN (94%), TE (93.2%), and non-suppressed at baseline (86.6%). LVS was observed in 0.7% (n = 14) of participants, with one participant developing resistance-associated mutations to nucleoside reverse transcriptase inhibitors (184 V) and integrase strand transfer inhibitors (263KR). Of the 131 (6.5%) treatment discontinuations, the most common reason was an adverse event (2.4%), with the most frequent being central nervous system/psychiatric (0.4%) and gastrointestinal (0.4%) toxicity. Median weight gain at week 48 was 2 kg (interquartile range -1 to 5), and a >10% weight increase was observed in 11.6% of participants.Conclusion: In this large real-world cohort, BIC/FTC/TAF showed excellent virological efficacy in a diverse population of patients with HIV. Rare occurrence of emergent drug resistance was observed, and treatment was well tolerated. | - |
dc.description.sponsorship | This study was supported by a grant provided by Gilead International. | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.rights | 2023 British HIV Association | - |
dc.subject.other | bictegravir/emtricitabine/tenofovir alafenamide | - |
dc.subject.other | efficacy | - |
dc.subject.other | HIV | - |
dc.subject.other | real-world data | - |
dc.subject.other | tolerability | - |
dc.title | Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 924 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | 914 | - |
dc.identifier.volume | 24 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Nasreddine, R (corresponding author), St Pierre Univ Hosp, Div Infect Dis, Rue Haute 322, B-1000 Brussels, Belgium. | - |
dc.description.notes | rakan.nasreddine@stpierre-bru.be | - |
local.publisher.place | 111 RIVER ST, HOBOKEN 07030-5774, NJ USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1111/hiv.13493 | - |
dc.identifier.pmid | 37038245 | - |
dc.identifier.isi | 000967527300001 | - |
dc.contributor.orcid | Nasreddine, Rakan/0000-0002-1265-1500; Van Praet, Jens | - |
dc.contributor.orcid | Tomas/0000-0002-7125-7001; Darcis, Gilles/0000-0001-8192-1351 | - |
dc.identifier.eissn | 1468-1293 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Nasreddine, Rakan; Delforge, Marc; De Wit, Stephane] St Pierre Univ Hosp, Brussels, Belgium. | - |
local.description.affiliation | [Florence, Eric] Inst Trop Med, Antwerp, Belgium. | - |
local.description.affiliation | [Yombi, Jean Cyr] Clin Univ St Luc, Brussels, Belgium. | - |
local.description.affiliation | [Henrard, Sophie] Erasme Univ Hosp, Univ Clin Brussels, Brussels, Belgium. | - |
local.description.affiliation | [Darcis, Gilles] Liege Univ Hosp, Liege, Belgium. | - |
local.description.affiliation | [Van Praet, Jens] AZ Sint Jan Brugge Oostende, Brugge, Belgium. | - |
local.description.affiliation | [Vandekerckhove, Linos D.] Ghent Univ Hosp, Ghent, Belgium. | - |
local.description.affiliation | [Allard, Sabine] Univ Ziekenhuis Brussel, Brussels, Belgium. | - |
local.description.affiliation | [Demeester, Remy] Univ Hosp Charleroi, Charleroi, Belgium. | - |
local.description.affiliation | [Messiaen, Peter] Jessa Hosp, Hasselt, Belgium. | - |
local.description.affiliation | [Ausselet, Nathalie] UCL Univ Hosp Namur Godinne, Yvoir, Belgium. | - |
local.uhasselt.international | no | - |
item.fullcitation | Nasreddine, Rakan; Florence, Eric; Yombi, Jean Cyr; Henrard, Sophie; Darcis, Gilles; Van Praet, Jens; Vandekerckhove, Linos D.; Allard, Sabine; Demeester, Remy; MESSIAEN, Peter; Ausselet, Nathalie; Delforge, Marc & De Wit, Stephane (2023) Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium. In: HIV MEDICINE, 24 (8) , p. 914-924. | - |
item.contributor | Nasreddine, Rakan | - |
item.contributor | Florence, Eric | - |
item.contributor | Yombi, Jean Cyr | - |
item.contributor | Henrard, Sophie | - |
item.contributor | Darcis, Gilles | - |
item.contributor | Van Praet, Jens | - |
item.contributor | Vandekerckhove, Linos D. | - |
item.contributor | Allard, Sabine | - |
item.contributor | Demeester, Remy | - |
item.contributor | MESSIAEN, Peter | - |
item.contributor | Ausselet, Nathalie | - |
item.contributor | Delforge, Marc | - |
item.contributor | De Wit, Stephane | - |
item.fulltext | With Fulltext | - |
item.accessRights | Restricted Access | - |
crisitem.journal.issn | 1464-2662 | - |
crisitem.journal.eissn | 1468-1293 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
HIV Medicine - 2023 - Nasreddine.pdf Restricted Access | Published version | 242.54 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.